口服伊达比星治疗晚期非小细胞肺癌（NSCLC）的II期试验。

Phase II trial of oral idarubicin in advanced non-small cell lung cancer (NSCLC).

作者信息

Ardizzoni A, Pronzato P, Repetto L, De Palma M, Canobbio L, Gulisano M, Fusco V, Rosso R, Ganzina F

机构信息

Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.

出版信息

Cancer Invest. 1988;6(4):409-11. doi: 10.3109/07357908809080069.

DOI:10.3109/07357908809080069

PMID:2846128

Abstract

The antitumoral activity and toxicity of a new daunorubicin analog (4-demethoxydaunorubicin, IMI 30, Idarubicin) was tested in 20 consecutive patients with non-small cell lung cancer mostly pretreated with chemotherapy. The drug was administered orally at a dose of 15 mg/m2 for three days every 3-4 weeks. There were no clinical responses. Hematological and nonhematological toxicities were mild.

摘要

一种新的柔红霉素类似物（4-去甲氧基柔红霉素，IMI 30，伊达比星）的抗肿瘤活性和毒性在20例连续性非小细胞肺癌患者中进行了测试，这些患者大多曾接受过化疗。该药物口服给药，剂量为15mg/m²，每3 - 4周服用三天。未观察到临床反应。血液学和非血液学毒性均较轻。